Abstract
Oral delivery of poorly bioavailable therapeuticals is challenging. The challenges are more serious when physiological factors of gut such as cytochrome P450, P-glycoprotein, permeability, pH triggered precipitation and degradation are responsible for poor bioavailability. P-Glycoprotein mediated multidrug resistance is on high agenda for anti-cancer drugs. The present article compiled different methodologies used to curb these challenges of bioavailability. The concepts of poor bioavailability are illustrated along with possible management. Numerous relevant patents for bioavailability enhancement are also highlighted. Though, there is no universal approach for bioavailability enhancement, the drug related challenges are managed by altering its physicochemical characteristics or employing formulation technology, while the effects of physiological factors are minimized by using efflux transport inhibitor or cytochrome P-450 inhibitor or prodrug or through formulation technologies (enteric coating or microenvironment of pH etc.).
Keywords: Bioavailability, cytochrome P-450, gastrointestinal tract, P-glycoprotein, multidrug resistance, prodrug.
Recent Patents on Anti-Cancer Drug Discovery
Title:Understanding and Managing Oral Bioavailability: Physiological Concepts and Patents
Volume: 10 Issue: 1
Author(s): Mohd A. Alam, Fahad I. Al-Jenoobi, Abdullah M. Al-Mohizea and Raisuddin Ali
Affiliation:
Keywords: Bioavailability, cytochrome P-450, gastrointestinal tract, P-glycoprotein, multidrug resistance, prodrug.
Abstract: Oral delivery of poorly bioavailable therapeuticals is challenging. The challenges are more serious when physiological factors of gut such as cytochrome P450, P-glycoprotein, permeability, pH triggered precipitation and degradation are responsible for poor bioavailability. P-Glycoprotein mediated multidrug resistance is on high agenda for anti-cancer drugs. The present article compiled different methodologies used to curb these challenges of bioavailability. The concepts of poor bioavailability are illustrated along with possible management. Numerous relevant patents for bioavailability enhancement are also highlighted. Though, there is no universal approach for bioavailability enhancement, the drug related challenges are managed by altering its physicochemical characteristics or employing formulation technology, while the effects of physiological factors are minimized by using efflux transport inhibitor or cytochrome P-450 inhibitor or prodrug or through formulation technologies (enteric coating or microenvironment of pH etc.).
Export Options
About this article
Cite this article as:
Alam A. Mohd, Al-Jenoobi I. Fahad, Al-Mohizea M. Abdullah and Ali Raisuddin, Understanding and Managing Oral Bioavailability: Physiological Concepts and Patents, Recent Patents on Anti-Cancer Drug Discovery 2015; 10 (1) . https://dx.doi.org/10.2174/1574892809666140917103834
DOI https://dx.doi.org/10.2174/1574892809666140917103834 |
Print ISSN 1574-8928 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3970 |
Call for Papers in Thematic Issues
Novel anti-cancer drugs in photoimmunotherapy management: from bench to translational research
In recent years, traditional cancer treatments, such as surgery, chemotherapy, and radiation treatment, etc., may damage the pathological tissue and normal cells. The ideal tumor treatment should be noninvasive, eliminating the primary tumor, making the body produce systemic tumor-specific immunity, eliminating metastases, and having less /no side effects. Recent Patents ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Gold Nanoparticles as Targeted Delivery Systems and Theranostic Agents in Cancer Therapy
Current Medicinal Chemistry Antagonizing IL-6 in Ankylosing Spondylitis: A Short Review
Inflammation & Allergy - Drug Targets (Discontinued) Biofabrication of Reduced Graphene Oxide Nanosheets using Terminalia Bellirica Fruit Extract
Current Nanoscience Carbonic Anhydrases An Overview
Current Pharmaceutical Design Clioquinol – A Novel Copper-Dependent and Independent Proteasome Inhibitor
Current Cancer Drug Targets Biomarker Diversity, Validation and Clinical Translation: Tenets for Emergent Personalized Medicine Initiatives
Current Pharmacogenomics and Personalized Medicine Structure, Function and Inhibition of Poly(ADP-ribose)polymerase, Member 14 (PARP14)
Mini-Reviews in Medicinal Chemistry Tubulin Colchicine Binding Site Inhibitors as Vascular Disrupting Agents in Clinical Developments
Current Medicinal Chemistry Editorial [A Transdisciplinary Forum for Study of Individual and Population Variability in Response to Health Interventions and Personalized Medicine]
Current Pharmacogenomics and Personalized Medicine Spontaneous Pneumothorax
Current Respiratory Medicine Reviews Protein Kinase C Modulates Aurora-kinase Inhibition Induced by CCT129202 in HMC-1560,816 Cell Line
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry MDM2 Increases Drug Resistance in Cancer Cells by Inducing EMT Independent of p53
Current Medicinal Chemistry Editorial [Hot Topic: Natural Compounds as Cancer Chemopreventive and Chemotherapeutic Agents: Insights Gained from Mechanistic and Pharmacologic Studies]
Anti-Cancer Agents in Medicinal Chemistry Cellular Senescence in the Development and Treatment of Cancer
Current Pharmaceutical Design Chemical Modifications of Two Polysaccharides as Drug Carriers
Current Organic Synthesis Cationic Lipids for Transfection
Current Medicinal Chemistry Drug Delivery Based on Nanotechnology for Target Bone Disease
Current Drug Delivery HSP60 as a Drug Target
Current Pharmaceutical Design Why Some Messages Speak Better: Child Immunization in the News and on the Internet
Current Drug Safety Pharmacological Targeting of the Inflamed Intestinal Barrier
Current Pharmaceutical Design